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Abstract
Introduction: Ataxia telangiectasia (AT) is a rare human neurodegenerative
autosomal recessive multisystem disease. AT is the result of mutations in the
AT-mutated (ATM) gene. ATM protein is required for radiation-induced apoptosis
and acts before mitochondrial collapse. The tRNA genes are considered one of
the hot spots for mutations causing mitochondrial disorders. Due to the
important role of ATM in apoptosis and its effect on the cell cycle it might be
possible that it has a central role in mtDNA mutations. On the other hand, the
tRNALys/Leu gene and also ATPase6 and ATPase8 genes are important for many
mitochondrial diseases and many causative mutations have been reported from
these genes. 
Material and methods: In the present research, we performed mutation screening
for these genes in 20 patients who were diagnosed with ataxia telangiectasia
by a PCR sequencing method.
Results: The results showed a significant level of mtDNA variations in AT patients.
Among 20 patients in this study, 12 patients (60%) were detected with point
mutations, among which 8 mutations (40%) belonged to the MT-ATP6 gene.
There was probably a second effect of mtDNA mutations in AT disease and
mtDNA plays a main role in establishment of AT.
Conclusions:  MtDNA mutations might be responsible for the decline of
mitochondrial function in AT patients. Mitochondrial investigation can help to
understand the mechanism of damage in AT disease.
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Introduction
Ataxia telangiectasia (AT) is a rare, neurodegenerative, autosomal
recessive inherited disease that affects a number of different organs in
the body and causes severe disability during childhood. About 20% of
patients with AT develop cancer, particularly acute lymphocytic leukaemia
or lymphoma. Many of these patients have been reported to have an
impaired immune system, making them susceptible to recurrent respiratory
infections. Ataxia telan  giectasia is caused by mutations to the ATM (ataxia
telangiectasia mutated) gene, which has been identified, sequenced and
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Copyright © 2011 Termedia & Banachis located primarily on chromosome 11q22-23.
Ataxia telangiectasia patients have shown more
than 400 distinct ATM mutations, of which 85% are
null mutations [1, 2]. The ATM protein is a member
of the phospha  tidylinositol 3-kinase-like family of
serine/threonine protein kinases (PIKK) [3, 4]. Ataxia
telangiectasia mutated protein is required for
radiation-induced apoptosis and acts before
mitochondrial collapse [5]. This protein is also
involved in cell cycle control, intracellular protein
transport, and the DNA damage response.
Apoptosis is induced either through the death
receptor pathway of apoptosis, or the mitochondrial
pathway of apoptosis. This protein also plays a role
in normal development and activity of body
systems such as the nervous and immune system,
which obviously indicates that any problem in the
functions of the ATM protein could lead to immune
system related diseases.
Mitochondria are present in almost all mam  -
malian cells, and are responsible for energy gene  -
ration. Despite the fact that the mitochondrial
genome is very small, mitochondrial DNA mutations
have an important role in genetic diseases [6, 7].
Mitochondrial DNA (mtDNA) mutations can result
in both maternally inherited and sporadic diseases.
The mitochondrial genome is 16.6-kb double-
stranded circular DNA encoding 37 genes, including
13 proteins, 22 transfer RNAs, and 2 ribosomal RNAs.
A number of mutations in the mitochondrial (mt)
tRNA genes have been reported to be associated
with human mitochondrial diseases. 
It has been reported that the ATM protein is
involved in regulation of cell check points and
mutations leading to apoptosis, leaving us to
hypothesize that mitochondrial DNA could play
a role in AT patients who develop cancer, especially
in the apoptotic pathway [8]. Many exhaustive
screening approaches have been applied to
investigate the mutations in mtDNA causing various
human diseases. Many scientists have reported that
point mutations in tRNALys/Leu genes and ATPase 6
and 8 genes are the leading causes of mitochondrial
disorders [9]. To elucidate the molecular and
functional role of mtDNA in patients with AT, it is
required to establish that the mutations to
mitochondrial (mt) tRNA could lead to the
mitochondrial pathway of apoptosis in AT patients. 
In this study we performed screening of
mutations to the tRNALys/Leu genes and ATPase 6
and 8 genes in Iranian patients with AT who were
referred to our centre. Primers for mitochondrial
tRNALys/Leu and ATPase 6 genes were used on the
DNA extracted from the blood samples of these
patients and amplified by PCR. Automated DNA
sequencing of the amplified DNA led to detection
of possible DNA mutations in the mitochondrial (mt)
tRNALys/Leu and ATPase 6 genes. Our additional
analysis suggested that the presence of these
mutations could be one of the causes of
mitochondrial dysfunction in these AT patients
leading to cancer.
Material and methods
Diagnosis of ataxia telangiectasia patients
All the patients were clinically defined as having
AT by a neurologist according to generally accepted
diagnosis criteria of AT [10]; all of the patients had
gait ataxia, oculocutaneous telangiectasias, apraxia
of eye movement or immunological defects that
include immunoglobulin deficiencies (particularly
IgA and IgE), high serum α-fetoprotein concentration
and lymphopenia. If the diagnosis was uncertain,
molecular genetic tests for ATM mutations were
performed to confirm the diagnosis [2].
Analysis of tRNALys/Leu genes and ATPase genes
Mutation screening of tRNALys/Leu genes and also
ATPase6 genes was performed in 20 patients who
were diagnosed based on the typical clinical
features of ataxia telangiectasia. Peripheral blood
samples were obtained and the DNA was purified
using a Diatom DNA Extraction Kit (Genefanavaran,
Tehran).
Two pairs of primers were used to amplify the
targeted genes. The primers and the PCR conditions
were replicated from previous studies [11, 12]. The
nucleotide sequences were directly determined by
automated sequencing in a 3700 ABI machine using
forward primers (Macrogene Seoul, Korea). The
obtained mtDNA sequences were aligned with
a multiple sequence alignment interface CLUSTAL_X
with comparison to Mitomap references (http:
/www.gen.emory.edu/mitomap/ mitoseq.html).
Results
The sequence analysis of samples showed the
following mutations: A8774G, A8982C and C8684T
in the mt-ATPase6 gene. Each mutation was found
in one patient out of 20. These mutations in the
MT-ATPase6 gene result in amino acid replacements.
In 6 patients, an mtDNA polymorphism without
changing the amino acid was identified. The
findings showed six known polymorphisms in the
mt-ATP6 gene. All of the variations were homo  -
plasmic based on the sequencing results. Nucleotide
changes in mitochondrial genes found in our
patients are shown in Table I [18-26]. Nucleotide
changes in mitochondrial tRNALeu were not found
in the studied patients.
Discussion
A prominent characteristic of mtDNA diseases is
that tissues with a high energy demand, such as
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muscle and brain, are mostly affected [7]. Based on
other investigations on Iranian AT patients, mtDNA
deletions have been observed in about 54% of the
patients. The discovered deletions remove or impair
some structural genes including ATPase 6 and 8,
COIII, ND3, ND4L, ND4, ND5, ND6, Cytb and eight
tRNA genes. Such deletions in AT patients may
result in multiple respiratory chain deficiencies [13].
The human mtDNA encodes 13 polypeptides that
are essential for the mitochondrial energy
generating system, oxidative phosphorylation
(OXPHOS), as well as the tRNA genes which are
necessary for their expression; thus, any mutation
in the mtDNA coding region will alter mitochondrial
energy production. Series of enzyme complexes are
present in the mitochondria inner membrane which
are known collectively to constitute the electron
transport chain which consists of five complexes.
Complex V (ATP synthase) is composed of 14
subunits. The protons expelled from other
complexes create an electrochemical gradient for
ATP production. Human mtDNA encodes 2 subunits
(ATPases 6 and 8) of complex V subunits [14]. So
any mutation in these genes may also disorganize
the mitochondrial energy production processes.
Defective energy metabolism resulting from loss of
ATP production is certainly a common attribute of
most OXPHOS diseases [6]. For example, point
mutations in the ATP synthase subunit 6 have been
observed in some disease including neuropathy
ataxia retinitis pigmentosa (NARP) and Leigh
syndromes [15].
Mitochondria use OXPHOS to generate most of
the cellular ATP and as a toxic product they produce
most of the endogenous reactive oxygen species
(ROS). The ROS can damage the OXPHOS enzymes
and mtDNA in turn, eroding mitochondrial function.
In the presence of mtDNA mutations which may be
caused by ROS during aerobic metabolism, sensitive
cells such as skeletal muscles are deprived of ATP
(due to the defective respiratory functions of
mitochondria). Apoptosis is induced either through
the death receptor pathway of apoptosis, or the
mitochondrial pathway of apoptosis. When
mitochondrial energy production gets too low
and/or mitochondrial ROS damage becomes too
high, similar to the condition happening in AT
patients, the mitochondrial permeability transition
pore (mtPTP) is activated and the cell is removed
by apoptosis, thus resulting in more profound
oxidative damage [16].
Since point mutations of mitochondrial tRNA
genes are the hot spots of mitochondrial disorders,
in this research the sequence of mitochondrial
tRNALys/Leu genes and ATPase genes of 20 AT
patients were analysed by PCR and automated
sequencing methods. The results showed a signi  -
ficant level of mtDNA variations in AT patients. In
one case a nucleotide variation (C8684T) resulting
in amino acid change from Thr to Ile was observed
in the MT-ATPase6 gene. Thr is categorized in polar
amino acids, but Ile contains non-polar properties.
This alteration may strongly affect the tertiary
structure of protein that will impair its interaction
with ATP .
Moreover, two samples in this study showed
novel point mutations in the MT-ATP6 gene causing
amino acid replacement. The first one was A8982C
Number Nucleotide Locus Nucleotide  Amino acid  Report Reference 
position change change
1 8774 MT-ATP6 A-G N-S No
2 8684 MT-ATP6 C-T T-I Yes Unpublished 
MtDNA polymorphism, 
Arabs from Saudi Arabia
3 8277 MT-NC7 T-C Non-coding region Yes 18
4 8697 MT-ATP6 G-A Syn Yes 19-21
5 8574 MT-ATP6 C-T Syn No
6 8562 MT-ATP6 C-T Syn No
7 8982 MT-ATP6 A-C Q-H No
8 8730 MT-ATP6 A-G Syn No
9 8562 MT-ATP8 C-T P-L No
10 8292 MT-NC7 G-A Non-coding region No
11 8269 MT-COII G-A Non-coding region Yes 21-23
12 8856 MT-ATP6 G-A Syn Yes 19, 24-26
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mutation in an affected patient which changes Gln
to His. Gln has neutral properties but His is a basic
amino acid. Therefore, it could deeply influence the
structure of the subunit of respiratory complex V
and the activity of this complex as a result.
Regarding the second sample, we found a point
mutation at position 8774 in the MT-ATP6 gene that
alters Asn to Ser, where both of the amino acids
have similar properties. Neither of these variations
have been reported previously.
In the present research, approximately 60% of
our patients had mtDNA mutations. Among the 12
mitochondrial mutations in this study, four of them
(~30%) were missense mutations. Three of the
patients (25%) in this study had mutations in the
non-coding region of the MT-NC7 gene. All of the
mutations in the coding region belonged to the mt-
ATP6 gene with the exception of one variation in
the mt-ATP8 gene.
Recent studies proposed involvement of
mitochondrial pathway mediated apoptosis in the
development of cancers in this group of patients
and in immunopathogenesis of AT. In fact, apoptosis
in AT could be via the mitochondrial pathway, which
would offer a basis for establishment of mtDNA-
targeted therapeutic interventions in AT [8].
Ataxia telangiectasia mutated is the gene
mutated in ataxia telangiectasia and numerous
different mutations in the ATM gene have been
identified in classical AT and in some patients with
variant forms of AT [17-26]. It was explained by
Eaton et al. (2007) that their results show a novel
function for ATM in mtDNA main  tenance. This study
hypothesizes that since ATM influences the de novo
pathway for dNTP synthesis which is required for
mtDNA replication and repair, and also since AT cells
have higher amounts of ROS, the loss of ATM will
affect the mtDNA copy number. Finally they offered
novel roles for ATM in mitochondrial homeostasis. 
Based on our results, there was probably
a second effect of mtDNA mutations in AT disease
and mtDNA plays a main role in establishment of AT.
Perhaps mtDNA mutations are responsible for the
decline of mitochondrial function in AT patients. In
conclusion, we suggest more analysis to unravel
the precise connection between ATM, mtDNA
mutations and AT disease. 
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